Navigation Links
Initial trials on new ovarian cancer tests exhibit extremely high accuracy
Date:8/11/2010

Scientists at the Georgia Institute of Technology have attained very promising results on their initial investigations of a new test for ovarian cancer. Using a new technique involving mass spectrometry of a single drop of blood serum, the test correctly identified women with ovarian cancer in 100 percent of the patients tested. The results can be found online in the journal Cancer Epidemiology, Biomarkers, & Prevention Research.

"Because ovarian cancer is a disease of relatively low prevalence, it's essential that tests for it be extremely accurate. We believe we may have developed such a test," said John McDonald, chief research scientist at the Ovarian Cancer Institute (Atlanta) and professor of biology at Georgia Tech.

The measurement step in the test, developed by the research group of Facundo Fernandez, associate professor in the School of Chemistry and Biochemistry at Tech, uses a single drop of blood serum, which is vaporized by hot helium plasma. As the molecules from the serum become electrically charged, a mass spectrometer is used to measure their relative abundance. The test looks at the small molecules involved in metabolism that are in the serum, known as metabolites. Machine learning techniques developed by Alex Gray, assistant professor in the College of Computing and the Center for the Study of Systems Biology, were then used to sort the sets of metabolites that were found in cancerous plasma from the ones found in healthy samples. Then, McDonald's lab mapped the results between the metabolites found in both sets of tissue to discover the biological meaning of these metabolic changes.

The assay did extremely well in initial tests involving 94 subjects. In addition to being able to generate results using only a drop of blood serum, the test proved to be 100 percent accurate in distinguishing sera from women with ovarian cancer from normal controls. In addition it registered neither a single false positive nor
'/>"/>

Contact: David Terraso
david.terraso@comm.gatech.edu
404-385-2966
Georgia Institute of Technology
Source:Eurekalert

Page: 1 2

Related biology news :

1. HSBC Climate Partnership yields initial research findings
2. Nervy research: Researchers take initial look at ion channels in a model system
3. Fish fend off invading germs with an initial response similar to the one found in people
4. Faster, cheaper way to find disease genes in human genome passes initial test
5. Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action
6. International Serious Adverse Events Consortium announces initial study results in its global research collaboration to identify genetic markers related to drug induced liver injury
7. Genetic testing not cost-effective in guiding initial dosing of common blood thinner
8. Efavirenz-based initial therapies associated with better outcomes in HIV-infected adults
9. Pioneering Use of Mobile Technology to Conduct Clinical Trials in Emerging Economies
10. UF oncologists fight leukemia with two-pronged therapy, clinical trials planned
11. Pitt gets $12 million DoD contract for regenerative medicine treatment trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... have developed a unique method to use microbes buried ... areas. , The first microbe-powered, self-sustaining wastewater treatment ... to clean up waste from large farming operations and ... Professor Haluk Beyenal and graduate student Timothy Ewing in ... system in the online edition of Journal of ...
(Date:9/18/2014)... 18, 2014 New research into the Crimean-Congo hemorrhagic ... severe hemorrhagic disease in humans similar to that caused ... CCHFV infection. This discovery has the potential to lead ... , The research, reported in a paper ... and conducted by scientists at the Texas Biomedical Research ...
(Date:9/18/2014)... how many times it,s demonstrated, it,s still hard ... , But by using a signaling system called ... behavior to suit their population. In short, some ... and act accordingly. , Once the population of ... from innocuous to pathogenic, or from unhelpful to ...
Breaking Biology News(10 mins):Researchers develop unique waste cleanup for rural areas 2Research milestone in CCHF virus could help identify new treatments 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3
... have come up with a new twist in their efforts ... DNA genetic code. They have developed the first, versatile DNA ... key to unlocking the vital code behind human heredity and ... director of the Biodesign Institute,s Center for Single Molecule Biophysics, ...
... 2010) For years, doctors have warned patients to finish ... "superbug" that can mount a more powerful defense against the ... engineers indicates that treating bacteria with levels of antibiotics insufficient ... wide range of antibiotics. In the Feb. 12 issue ...
... help save the sight of patients with a type of ... University of Leeds found that the TSPAN12 gene is faulty ... Vitreoretinopathy), which affects the development of the eye. While ... of the same family may carry the faulty gene without ...
Cached Biology News:ASU scientists develop universal DNA reader to advance faster, cheaper sequencing efforts 2ASU scientists develop universal DNA reader to advance faster, cheaper sequencing efforts 3Low levels of antibiotics cause multidrug resistance in 'superbugs' 2Low levels of antibiotics cause multidrug resistance in 'superbugs' 3New gene discovery could help to prevent blindness 2
(Date:9/22/2014)... 2014 Research and Markets has ... Microcrystalline Cellulose Industry Report 2014" report to their ... Cellulose Industry Report 2014 is a professional and in-depth ... cellulose industry with a focus on the Chinese situation. ... the industry including definitions, classifications, applications and industry chain ...
(Date:9/22/2014)... and TORONTO , Sept. ... www.generex.com ) (OTCBB:GNBT) today announced that it has ... (UHN) pursuant to which UHN,s Centre for Molecular ... buccal insulin refinement project.  The goal of the ... Generex Oral-lyn™, the Company,s proprietary buccal insulin spray ...
(Date:9/22/2014)... FierceBiotech today announced its annual “Fierce ... of 2014. FierceBiotech editors John Carroll and Damian ... winners. Those selected are identified as some of ... , "It's always a lot of fun ... companies," said Carroll. "This year in particular you'll find ...
(Date:9/22/2014)... , September 22, 2014 ... on a mixed note as the Dow Jones Industrial ... Composite closed at 4,579.79, down 0.30%. The S&P 500 ... trading session, six out of ten sectors finished on ... Index ended the day at 751.48, up 0.10%, with ...
Breaking Biology Technology:Global and Chinese Microcrystalline Cellulose Industry Report 2014 2Generex Collaborates with University Health Network for Buccal Insulin Project 2Generex Collaborates with University Health Network for Buccal Insulin Project 3Generex Collaborates with University Health Network for Buccal Insulin Project 4FierceBiotech Announces Annual “Fierce 15” Winners of 2014 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5
... Md., Sept. 2 Micromet, Inc.,(Nasdaq: MITI ... novel, proprietary antibodies for the treatment of cancer,inflammation ... A. Phillips as Senior Vice President and Chief ... of the Company,s board of directors,since 2000, and ...
... a New Jersey-based,leading provider of prescription co-pay programs ... significantly expanded the scope of,the lawsuit that it ... the State,of New York, County of New York, ... of McKesson Corporation. PSKW is,now seeking, in addition ...
... The BEAUTIFUL study: a step further in title ... BEAUTIFUL study: efficacy of session title ivabradine in reduction of cardiovascular ... among patients with stable coronary ... dysfunction, ESC Hotline ...
Cached Biology Technology:Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 2Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 3Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 4PSKW Expands Its Lawsuit Against McKesson to Seek Assignment of McKesson's Patent Application 2With the BEAUTIFUL Results, Procoralan* (ivabradine) is the First Antianginal Treatment Shown to Reduce Myocardial Infarction (Heart Attack) and Revascularisation in Stable Coronary Patients 2With the BEAUTIFUL Results, Procoralan* (ivabradine) is the First Antianginal Treatment Shown to Reduce Myocardial Infarction (Heart Attack) and Revascularisation in Stable Coronary Patients 3
... Ambions 96 well Magnetic-Ring Stand is ... 96 well U-bottom microplates. The stand has ... 96 well microtiter plate footprint. The use ... enables fast and easy magnetic separation. With ...
... from Thermus aquaticus expressed in E. coli; ... of 250 units enzyme/tube and Buffer I ... the same enzyme as AmpliTaq DNA Polymerase ... separation process to ensure that contaminating bacterial ...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/L; 1 tube of 1, 000 units enzyme/tube w/Buffer II and MgCl2...
... is a versatile and easy-to use enzyme, ... GCpro Taq DNA Polymerase is prepared from ... containing the DNA polymerase I gene from ... processive 5'-3' DNA polymerase activity. Its inherent ...
Biology Products: